Clinical efficacy of platinum-based chemotherapy combined radiotherapy for cervical cancer
10.3760/cma.j.issn.1008-6315.2012.06.006
- VernacularTitle:同期单药铂类化疗联合放疗治疗宫颈癌的效果观察
- Author:
Zhiyuan XU
;
Lianxing LIN
;
Mingming YAN
- Publication Type:Journal Article
- Keywords:
Cervical neoplasms;
Radiotherapy;
Chemotherapy;
Nedaplatin;
Cisplatin
- From:
Clinical Medicine of China
2012;28(6):576-578
- CountryChina
- Language:Chinese
-
Abstract:
Objective To evaluate the clinical efficacy of platinum-based chemotherapy combined radiotherapy for cervical cancer.Methods From October 2008 to June 2010,61 patients with cervical cancer were treated by radiotherapy( conventional external radiation and after-loading brachytherapy,to a total dose of 8000- 8500 cGy)combined platinum-based chemotherapy (cisplatin or nedaplatin 20 mg/m2,one times per weeks) in our department.The clinical efficacy and side effects were evaluated.Results Among 61 patients,the short-term effective rate was 100％ ( 61/61 ) and 1-year survival rate was 85.2％ ( 52/61 ).There was no significant difference between cisplatin group and nedaplatin in 1-year survival rate ( 84.6％ vs.85.7％,x2 =0.014,P=0.095).Arrest of bone marrow at Ⅰ,Ⅱ,Ⅲ and Ⅳlevel occurred 5,24,5 and 1 patients in the cisplatin group,and 6,12,3 and 3 patients in the nedaplatin group.There was also no significant difference between these two groups in great mass side effects induced by chemoradiotherapy (x2 =6.402,P =0.171 ).Conclusion It is worth practising of platinum-based chemotherapy combined radiotherapy for cervical carcinoma.The side effects induced by chemoradiotherapy is low.
